Phase 2 Gene Therapy Trial Begins Enrollment

 

A phase 2 clinical trial assessing the safety and efficacy of a gene therapy approach to treatment of choroideremia has begun enrolling patients at the University of Miami Miller School of Medicine.

Researchers will deliver a wild-type copy of the Rab-escort protein 1 (REP1) gene using an adeno-associated virus (AAV2-REP1). The open-label study will enroll six male patients, each of whom will receive a single dose of AAV2-REP1 via subretinal injection.

Choroideremia, an X-linked recessive disease, is caused by mutations to genes that encode REP1. The disease, for which no treatment currently exists, affects 1 in 50 000 people.

 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.